Bristol-Myers Profit Beats Expectations, 2016 Guidance Raised

Bristol-Myers Squibb Co. reported first-quarter earnings that beat analysts’ predictions and raised its forecast for the year, as sales of key treatments like the cancer drug Opdivo and the blood thinner Eliquis rose.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.